Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G SAQsAntenatal care — maternal medicine

O&G SAQs · Antenatal care — maternal medicine

Preeclampsia prediction and prevention — structured SAQ (15 marks)

FRANZCOG-format structured SAQ on preeclampsia prediction and prevention: risk-factor assessment by the NICE and USPSTF checklist, the full aspirin and calcium prescription with ASPRE and Roberge evidence, the Fetal Medicine Foundation competing-risks model with SPREE performance data, and honest counselling about residual risk. Per-sub-part marking rubric included.

15 marks20 min4 min readVerification in progress

Target exams

FRANZCOGMRCOGABOG
On this page
Study tools

Target exams

FRANZCOGMRCOGABOG
Prompt
You are the registrar in the antenatal clinic. A 39-year-old G2P1 books at 10+2 weeks. Her first pregnancy ended in emergency caesarean at 31 weeks for preeclampsia with fetal growth restriction; the baby weighed 1,120 g. She has a body mass index of 36 kg/m2, is a non-smoker, and takes no medication. Her blood pressure today is 128/78 mmHg and urinalysis is clear. (a) Perform her preeclampsia risk assessment and state the model you are using and the decision it produces. (4 marks) (b) State your preventive prescription in full, with drug, dose, timing, start and stop gestations, and the trial evidence for each element. (5 marks) (c) Describe first-trimester combined screening: the inputs, the performance, and its advantage over the risk-factor checklist. (4 marks) (d) She asks whether aspirin will definitely stop it happening again. Outline what you say. (2 marks)

How this SAQ is marked

Twelve SAQs, 180 marks, two two-hour papers — about 15 marks and 20 minutes each. This question rewards a prescription, not a discussion: name the model, name the drug, name the dose, name the gestations, name the trial. [3][1]

Reveal model answer and mark schemeShowHide

(a) Risk assessment (4 marks)

One mark for naming the model, two for correctly identifying her factors, one for the decision. [3][8]

  • Model used: the risk-factor checklist adopted by NICE, the USPSTF and ANZ practice — one high-risk factor, or two moderate-risk factors, triggers aspirin.[3][8]
  • High-risk factors present: previous hypertensive disease in pregnancy (preeclampsia at 31 weeks). That alone is sufficient.[3]
  • Moderate-risk factors present: age 40 years or more is not yet met at 39, but booking body mass index of 35 kg/m2 or more is present. Multiparity means nulliparity does not apply.[3]
  • Decision: she qualifies on a single high-risk factor, so she starts aspirin today. Her early-onset index disease also puts her at the higher end of recurrence risk — the pooled recurrence of preeclampsia is around one in five and rises the earlier and more severe the index episode.[9][3]

(b) The preventive prescription (5 marks)

One mark each for: drug and dose; start gestation; stop gestation; calcium with its indication; the trial evidence. [1][2][7]

ElementPrescription
Drug and doseLow-dose aspirin; ASPRE used 150 mg nightly. ANZ practice commonly 100 to 150 mg daily; NICE 75 to 150 mg; USPSTF 81 mg daily
Timing of the doseAt night, as in ASPRE and FIGO guidance
StartIdeally 11 to 14 weeks and no later than 16 weeks
Stop36 weeks in ASPRE; continuing to birth is also acceptable practice
Calcium1.5 to 2 g elemental calcium daily from around 20 weeks if dietary intake is low
[1][3][7][8]
  • ASPRE: 1,776 women at high risk by the competing-risks model, aspirin 150 mg nightly from 11 to 14 weeks until 36 weeks. Preterm preeclampsia fell from 4.3% to 1.6% (odds ratio 0.38, 95% CI 0.20 to 0.74; P = 0.004), with no significant excess of neonatal adverse events.[1]
  • Roberge dose-response meta-analysis: 45 trials, 20,909 women, doses 50 to 150 mg. Started at or before 16 weeks, aspirin reduced preeclampsia (RR 0.57), severe preeclampsia (RR 0.47) and fetal growth restriction (RR 0.56), each with a significant dose-response. Started after 16 weeks the effect on preeclampsia shrank to RR 0.81 with no dose-response, and there was no effect on severe preeclampsia or growth restriction.[2]
  • Calcium: the Cochrane review found high-dose calcium (1 g per day or more) may reduce preeclampsia and preterm birth, particularly with low-calcium diets, and reduces the composite of maternal death or serious morbidity, on low-quality evidence.[7]
  • State what you will not offer: bed rest, salt restriction, vitamins C and E, fish oil and garlic do not prevent preeclampsia.[4][8]

(c) First-trimester combined screening (4 marks)

One mark for the four inputs, one for the gestational window, one for performance, one for the comparison with the checklist. [6][5]

  • Window: 11 to 13+6 weeks, usually alongside the aneuploidy screen.[6]
  • Four inputs: maternal factors (age, weight, height, ethnicity, parity, obstetric and medical history, conception method); mean arterial pressure; uterine artery pulsatility index; and serum placental growth factor (PAPP-A as an alternative where placental growth factor is unavailable).[6]
  • Performance: O'Gorman reported detection of 75% of preterm preeclampsia and 47% of term preeclampsia at a 10% false-positive rate, with PAPP-A adding little once placental growth factor was included.[6]
  • Head-to-head: in SPREE (16,747 pregnancies) at a screen-positive rate of 10.3%, the NICE checklist detected 40.8% of preterm preeclampsia; maternal factors plus mean arterial pressure plus placental growth factor reached 69.0%; adding uterine artery pulsatility index reached 82.4%.[5]
  • The implementation caveat that earns the last mark: SPREE found compliance with the NICE recommendation to give first-trimester aspirin to high-risk women was only 23%. A better screen is worthless without the prescription.[5]

(d) Counselling about residual risk (2 marks)

One mark for honesty about relative rather than absolute protection, one for the surveillance and safety-net message. [1][9]

  • "Aspirin substantially reduces the chance of preeclampsia coming early, but it does not guarantee it will not happen. In the ASPRE trial the risk of preterm preeclampsia fell from about 4 in 100 to about 2 in 100 in women at high risk."[1]
  • "It has much less effect on preeclampsia at term, so we will still watch you closely: blood pressure and urine at every visit, growth scans, and a written list of symptoms that should bring you straight in."[1][8]
  • "If it does happen again, that will not be because you did anything wrong."[9]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References9ShowHide
  1. [1]Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia N Engl J Med, 2017.PMID 28657417
  2. [2]Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis Am J Obstet Gynecol, 2017.PMID 27640943
  3. [3]Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement JAMA, 2021.PMID 34581729
  4. [4]Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force JAMA, 2021.PMID 34581730
  5. [5]Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE Ultrasound Obstet Gynecol, 2018.PMID 29536574
  6. [6]O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation Am J Obstet Gynecol, 2016.PMID 26297382
  7. [7]Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems Cochrane Database Syst Rev, 2018.PMID 30277579
  8. [8]Shanmugalingam R, Barrett HL, Beech A, et al. A summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) hypertension in pregnancy guideline Med J Aust, 2024.PMID 38763516
  9. [9]Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis BJOG, 2018.PMID 29978553
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPreeclampsia diagnosis and management — structured SAQ (15 marks)Antenatal care — maternal medicineNextPregestational diabetes in pregnancy — structured SAQ (15 marks)Antenatal care — maternal medicine